BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1232 related articles for article (PubMed ID: 15207952)

  • 1. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
    Julius S; Kjeldsen SE; Weber M; Brunner HR; Ekman S; Hansson L; Hua T; Laragh J; McInnes GT; Mitchell L; Plat F; Schork A; Smith B; Zanchetti A;
    Lancet; 2004 Jun; 363(9426):2022-31. PubMed ID: 15207952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
    Zanchetti A; Julius S; Kjeldsen S; McInnes GT; Hua T; Weber M; Laragh JH; Plat F; Battegay E; Calvo-Vargas C; Cieśliński A; Degaute JP; Holwerda NJ; Kobalava J; Pedersen OL; Rudyatmoko FP; Siamopoulos KC; Störset O
    J Hypertens; 2006 Nov; 24(11):2163-8. PubMed ID: 17053536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.
    Assaad-Khalil SH; Najem R; Sison J; Kitchlew AR; Cho B; Ueng KC; DiTommaso S; Shete A
    Vasc Health Risk Manag; 2015; 11():71-8. PubMed ID: 25653536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
    Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
    Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control.
    Zappe D; Papst CC; Ferber P;
    Vasc Health Risk Manag; 2009; 5():883-92. PubMed ID: 19898644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study.
    Malacco E; Varì N; Capuano V; Spagnuolo V; Borgnino C; Palatini P;
    Clin Ther; 2003 Nov; 25(11):2765-80. PubMed ID: 14693303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The value of VALUE--a hypertension study which compared valsartan with amlodipine. New data support early, optimal blood pressure control for high-risk patients].
    Nilsson PM
    Lakartidningen; 2004 Jul; 101(30-31):2426-7. PubMed ID: 15314941
    [No Abstract]   [Full Text] [Related]  

  • 10. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.
    Mann J; Julius S
    Blood Press; 1998 May; 7(3):176-83. PubMed ID: 9758088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
    Corea L; Cardoni O; Fogari R; Innocenti P; Porcellati C; Provvidenza M; Meilenbrock S; Sullivan J; Bodin F
    Clin Pharmacol Ther; 1996 Sep; 60(3):341-6. PubMed ID: 8841157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.
    Julius S; Weber MA; Kjeldsen SE; McInnes GT; Zanchetti A; Brunner HR; Laragh J; Schork MA; Hua TA; Amerena J; Balazovjech I; Cassel G; Herczeg B; Koylan N; Magometschnigg D; Majahalme S; Martinez F; Oigman W; Seabra Gomes R; Zhu JR
    Hypertension; 2006 Sep; 48(3):385-91. PubMed ID: 16864741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
    Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH
    Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives.
    Weir MR; Ferdinand KC; Flack JM; Jamerson KA; Daley W; Zelenkofske S
    Hypertension; 2005 Sep; 46(3):508-13. PubMed ID: 16116046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
    Ogihara T; Nakao K; Fukui T; Fukiyama K; Ueshima K; Oba K; Sato T; Saruta T;
    Hypertension; 2008 Feb; 51(2):393-8. PubMed ID: 18172059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valsartan Amlodipine Randomized Trial (VART): design, methods, and preliminary results.
    Nakayama K; Kuwabara Y; Daimon M; Shindo S; Fujita M; Narumi H; Mizuma H; Komuro I
    Hypertens Res; 2008 Jan; 31(1):21-8. PubMed ID: 18360014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.
    Weber MA; Julius S; Kjeldsen SE; Brunner HR; Ekman S; Hansson L; Hua T; Laragh JH; McInnes GT; Mitchell L; Plat F; Schork MA; Smith B; Zanchetti A
    Lancet; 2004 Jun; 363(9426):2049-51. PubMed ID: 15207957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks].
    Praxis (Bern 1994); 2004 Oct; 93(42):1748. PubMed ID: 15529964
    [No Abstract]   [Full Text] [Related]  

  • 19. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
    Frampton JE; Scott LJ
    Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination.
    Trenkwalder P; Schaetzl R; Borbas E; Handrock R; Klebs S
    Blood Press Suppl; 2008 Dec; 2():13-21. PubMed ID: 19205092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.